Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Apr 27;25(1):118.
doi: 10.1186/s12902-024-01802-2.

Positive impact of mobile educational platforms on blood glucose control in patients with nephrotic syndrome and steroid-induced diabetes mellitus: a randomized controlled study

Zhimin Yang  1 , Zhicheng Tan  2 , Minna Sun  1 , Jing Zhang  1 , Haizhu Hou  1 , Xin Li  1
Affiliations
Randomized Controlled Trial

Positive impact of mobile educational platforms on blood glucose control in patients with nephrotic syndrome and steroid-induced diabetes mellitus: a randomized controlled study

Zhimin Yang et al. BMC Endocr Disord. .

Abstract

Objective: Steroid-induced diabetes mellitus (SDM) is a common complication in patients with nephrotic syndrome (NS) undergoing steroid therapy. Effective blood glucose control is critical for improving outcomes in these patients. This study evaluates the impact of mobile educational platforms on blood glucose control and patient adherence in patients with NS combined with SDM.

Methods: A randomised controlled study was conducted involving 56 patients with NS and SDM at Shanxi People's Hospital between April 2019 and December 2020. Participants were recruited using convenient sampling and were randomly assigned to either the intervention group (n = 28) or the control group (n = 28). The control group received routine health management, whereas the experimental group was provided with health management via a mobile educational platform. Blood glucose levels (fasting glucose and postprandial blood glucose), self-management efficacy and patient adherence to treatment were assessed over a 6-month period.

Results: The 56 participants included in the study had a mean age of 69.0 ± 10.5 years and an average diabetes duration of 7.2 ± 3.5 years. At the end of 6 months, the intervention group showed significant reductions in fasting blood glucose and postprandial blood glucose levels (P < 0.001). Self-management efficacy, assessed using the Diabetes Self-Efficacy Scale, improved significantly post-intervention (4.42 ± 0.53 vs. 4.15 ± 0.56, P = 0.020). Additionally, patient adherence to treatment improved by 25% in the intervention group compared with the control group.

Conclusion: The use of mobile educational platforms significantly resulted in better glycemic control and treatment adherence in the patients with NS and SDM compared to the control group. These findings suggest that integrating mobile health technologies into routine care can enhance disease management and optimise outcomes.

Trial registration: The study was retrospectively registered "ISRCTN23135945" on 05/11/2024.

Keywords: Blood glucose control; Mobile healthcare; Nephrotic syndrome; Self-management; Steroid-induced diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Shanxi Provincial People’s Hospital, [(2021) Provincial Medical Department Ethical Review No. (272)]. Informed consent was obtained from all participants prior to enrollment in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. AbuMaziad AS, Abusaleh R, Bhati S. Congenital nephrotic syndrome. J Perinatol. 2021;41(12):2704–12. 10.1038/s41372-021-01279-0. - PubMed
    1. De La Dumas C, Prezelin-Reydit M, Vermorel A, et al. Idiopathic nephrotic syndrome: characteristics and identification of prognostic factors. J Clin Med. 2018;7(9). 10.3390/jcm7090265. - PMC - PubMed
    1. Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022;18(9):540–57. - PMC - PubMed
    1. Salehidoost R, Korbonits M. Glucose and lipid metabolism abnormalities in Cushing’s syndrome. J Neuroendocrinol. 2022;34(8):e13143. 10.1111/jne.13143. - PubMed
    1. Shah P, Kalra S, Yadav Y, et al. Management of glucocorticoid-Induced Hyperglycemia. Diabetes Metab Syndr Obes. 2022;15:1577–88. 10.2147/DMSO.S330253. - PMC - PubMed

Publication types

LinkOut - more resources